Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

Contributed by: Business Wire

Images

Business Wire embedded0

Tags

Health

Medical Devices

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Neuraptive Therapeutics Inc.

More Like This

“The NEUROFUSE Study has yielded promising early clinical results consistent with preclinical studies of NTX-001,” said Evan Tzanis, Chief Operating Officer and EVP of R&D at Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves

Evan L. Tzanis, COO and EVP Head of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

Evan L. Tzanis, Chief Operating Officer and EVP of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain